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Abstract Vincristine, a critical component of combination chemotherapy treatment for
pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine-induced peripheral
neuropathy (VIPN). Longitudinal VIPN assessments were obtained over 12 months from
newly diagnosed children with ALL (N= 128) aged 1–18 years who received vincristine
at one of four academic children’s hospitals. VIPN assessments were obtained using the
Total Neuropathy Score-Pediatric Vincristine (TNS©-PV), National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE©), Balis© grading scale, and Pediatric
Neuropathic Pain Scale©–Five (PNPS©-5). Of children who provided a full TNS©-PV score,
85/109 (78%) developed VIPN (TNS©-PV ≥4). Mean TNS©-PV, grading scale, and pain
scores were low. CTCAE©-derived grades 3 and 4 sensory and motor VIPN occurred
in 1.6%/0%, and 1.9%/0% of subjects, respectively. VIPN did not resolve in months
8–12 despite decreasing dose density. VIPN was worse in older children. Partition cluster
analysis revealed 2–3 patient clusters; one cluster (n= 14) experienced severe VIPN. In
this population, VIPN occurs more commonly than previous research suggests, persists
throughout the first year of treatment, and can be severe.
Key words: acute lymphoblastic leukemia, children, patterns, severity, vincristine-induced
peripheral neuropathy
Introduction
Acute lymphoblastic leukemia (ALL), the most
common childhood cancer, was diagnosed in 2,670
children and 410 adolescents in the United States
in 2014 (American Cancer Society, 2014). Because of
advances in treatment, including the use of vincristine
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as a mainstay chemotherapeutic agent, the 5-year sur-
vival rate increased from 57% in 1975–1979 to 90%
in 2003–2009 (American Cancer Society, 2014). Many
children who undergo vincristine treatment experi-
ence vincristine-induced peripheral neuropathy (VIPN),
which affects sensory, motor, and autonomic nerves
(Toopchizadeh et al., 2009; Gomber et al., 2010; Anghe-
lescu et al., 2011; Argyriou et al., 2012). Moderate to
severe VIPN (grades 3 and 4) necessitates decreasing
the vincristine dose (Verstappen et al., 2005; Gomber
et al., 2010), which may affect cancer treatment effi-
cacy. VIPNmay not resolve over time, which negatively
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influences function and quality of life for years beyond
treatment completion (Postma et al., 1993; Ness et al.,
2013).
Although VIPN is recognized as a common adverse
effect of pediatric ALL treatment, little is known about
its true incidence, severity, clinical manifestations, and
patterns experienced over the first year of therapy,
due in part to the difficulty in accurately capturing
neuropathy in young children. In pediatric studies of
vincristine-based treatments for ALL, sarcoma, and
medulloblastoma, most authors report low National
Cancer Institute (NCI) Common Terminology Criteria
(CTCAE©)-derived grades 3 and 4 VIPN incidence rates
ranging from 0% to 37% (Vats et al., 1992; Kortmann
et al., 2000; Chauvenet et al., 2003; Bisogno et al.,
2005; Ramchandren et al., 2009; Messinger et al.,
2010; Messinger et al., 2012). The highest incidence
was reported when vincristine was administered with
other neurotoxic drugs (Kortmann et al., 2000). Inci-
dence rateswere also higher in studies reporting all lev-
els of VIPN severity, as opposed to just severe (grades
3 and 4) VIPN, and when more rigorous VIPN assess-
ment approaches were used, that is, clinical exam-
inations and electrophysiological studies (Verstappen
et al., 2005; Ramchandren et al., 2009; Toopchizadeh
et al., 2009). For example, rigorous VIPN assessment
revealed that nearly all participants (96% of n= 25)
developed VIPN (Toopchizadeh et al., 2009). Grading
scales, such as the CTCAE©, have been criticized for
being insensitive and unreliable (Postma et al., 1998;
Cavaletti et al., 2010; Griffith et al., 2010; Frigeni et al.,
2011; Cavaletti et al., 2013; Gilchrist et al., 2014). When
considering the high VIPN incidence reported in stud-
ies using rigorous assessment approaches as opposed
to the low VIPN incidence rates reported in studies
using the CTCAE©, it is clear that reliance on grading
scales to quantify VIPN in clinical trials has led to false
impressions about the scope of the problem.
Although young children are unable to describe
their VIPN symptoms (Gilchrist, 2012), clinicians often
rely on childrens’ self-report (Paice, 2009; Cavaletti
et al., 2010). Worsening neurotoxicity and appropriate
vincristine dose adjustments may be neglected, lead-
ing to worsening or permanent nerve damage.
Chronic, even if subtle, peripheral neuropathy over
a childhood cancer survivor’s lifetime may be sig-
nificant. For example, in a study of long-term sur-
vivors treated for pediatric malignancies, patients with
vincristine- or platinum-associated peripheral neuropa-
thy experienced chronic sensory impairment (Ness
et al., 2013). Motor deficits may result in decreased
physical activity, obesity, type 2 diabetes mellitus,
metabolic syndrome, and cardiovascular disease (Hoff-
man et al., 2013; Khan et al., 2014). Understanding
VIPN and identifying the highest risk children could
facilitate optimizing vincristine dosing for maximum
disease response while minimizing the risk of chronic
functional deficits.
We evaluated VIPN throughout treatment using
reliable, valid, sensitive, and responsive assessment
approaches to quantify the VIPN phenotype. Study
aimswere to describe (1) VIPN incidence, patterns, and
severity; (2) the relationship between dose density and
VIPN; and (3) predictors of more severe VIPN when
assessed over the first 12months of vincristine therapy
in children ages 1–18 with ALL.
Methods
Sample and setting
Children with newly diagnosed precursor B-cell
ALL (N= 128) were recruited from four academic medi-
cal centers: Indiana University School ofMedicine/Riley
Hospital for Children, the University of Michigan Com-
prehensive Cancer Center/Mott Children’s Hospital,
Vanderbilt University/Monroe Carell Jr Children’s Hos-
pital, and George Washington University/Children’s
National Medical Center. Participants were between
the ages of 1 and 18 at the time of diagnosis and
received vincristine according to Children’s Oncology
Group (COG) treatment trials (including AALL0232,
AALL0331, AALL08P1, or AALL0932). The standard
vincristine dosage received was 1.5mg/m2 (capped
at 2-mg maximum dose). Toxicity-based dose modifi-
cations were defined according to the specific COG
protocol guiding the individual child’s leukemia treat-
ment. The exclusion criteria were (1) baseline periph-
eral neuropathy score greater than grade 1 per the NCI
CTCAE© version 4.0; (2) currently receiving erythropoi-
etin, itraconazole, or vitamin supplement greater than
100% of the recommended daily allowance; (3) Down
syndrome; (4) pregnancy; and (5) a history of coexist-
ing serious illness that would limit neurological assess-
ments.
Measures
VIPN was assessed using the Total Neuropathy
Score (TNS©), NCI CTCAE© V.4.0, and the Modified
Balis Pediatric Scale of Peripheral Neuropathy© (Smith
et al., 2008). We used a TNS© subscale that had
been revised for use in children receiving vincristine
(TNS©-PV) (Table 1) (Smith et al., 2013).
VIPN-associated pain was measured using the
Pediatric Neuropathic Pain Scale©–Five (PNPS©-5).
The FACES© pain scale (Bosenberg et al., 2003; Hock-
enberry, 2005) was used to assist children to select a
PNPS©-5 pain severity rating. If the child did not under-
stand the question, parents/guardians estimated the
pain scores based on observations of their children.
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Table 1. Total Neuropathy Score©-Pediatric Vincristine
(TNS©-PV) (Cornblath, et al., 1999; Smith, et al., 2013).
Item Description
Worse subjective
symptom
The worse score obtained based
on the distal to proximal
extension of paresthesias,
numbness, and neuropathic
pain
Temperature sensibility Test distal to proximal
Vibration sensibility Test distal to proximal
Strength Toes, ankles, hips, hands,
thumbs, wrist, arm
Deep tendon reflexes Ankle, knee, supinator, triceps,
biceps
Autonomic neuropathy Constipation
Laryngeal neuropathy Vocal cord function (hoarseness)
Procedure
The study was approved by each site’s institu-
tional review board. If the subjects were eligible, par-
ent/guardian consent was obtained, along with the
child’s assent for children ≥7 years of age.
VIPN assessments using the TNS©-PV were
performed by trained evaluators (nurses, physicians,
mid-level providers, and students) who had passed a
competency examination judged by a pediatric neurol-
ogist. Neurologist-evaluator inter-rater reliability (IRR)
was assessed at each site periodically throughout
the study (methods reported elsewhere) (Smith et al.,
2013). TNS©-PV score correlations between neurol-
ogists and non-neurologist raters were moderate to
strong (r= 0.54–0.99) and IRR was better when the
alternative scoring approach was used (Smith et al.,
2013).
Subjects were evaluated for neuropathy and pain
at baseline (before day 8 vincristine) and, for the first
year, on each subsequent day of vincristine treatment
prior to vincristine administration.
Analyses
Only data from children who could provide com-
plete TNS©-PV scores were included in the analyses.
To assess for likelihood of selection bias, the demo-
graphic characteristics of children who could not pro-
vide a complete score were compared to the ana-
lyzed sample. Children with TNS©-PV score≥4 were
defined as having VIPN, a cut-point based on find-
ings that approximately 5% of pediatric normal con-
trols have a ped-mTNS© (a slightly different TNS©
variant) score of four or higher, and no normal con-
trols had scores≥5 (Gilchrist and Tanner, 2013). Data
were analyzed using descriptive statistics (frequencies,
means, and standard deviations [SDs]), two-tailed cor-
relations, paired t-tests, one-way ANOVA with Tukey’s
post hoc tests, and cluster analysis. Vincristine dose
density curves were calculated based on the kernel
density function. Finding patient groups showing sim-
ilar patterns for each of the items was accomplished
through a cluster analysis technique: the k-medoids or
Partition Around Medoids (PAM) technique (Kaufman
and Rousseeuw, 1987), which is a modification of the
standard k-means clustering method. The only differ-
ence from k-means is that each cluster in PAM is rep-
resented by one object (middle object or median-like
object) in the cluster instead of the cluster center. The
goal of the algorithm is to minimize the average dissim-
ilarity of objects to their closest selected object. We
also minimized the sum of the dissimilarities between
object and their closest selected object. Starting from
an initial set ofmedoids, the PAMmethod replaced one
of the medoids by a nonmedoid. When it improved the
aggregate similarity measure, we retained the swap.
This process was repeated for all medoid-nonmedoid
pairs. For the similaritymeasure, we used Euclidian dis-
tances which are root sum of squares of differences.
In our analysis, the pre-specified k value was 3 for 12
months. Missing data were imputed using the average
value of that month. Cluster analyses of TNS©-PV data
were conducted using the function pam in R 3.0.2.
Patients received vincristine every week during the
first 4weeks of treatment, but less frequently dur-
ing the maintenance period. To address this unbal-
anced dose–response relationship, we observed the
vincristine treatment density over all time points, and
transformed the dose time points into dose density. To
transform discrete time points into a continuous time
curve with the area under the curve equal to 1, the
dose density curve was computed using the density
function in R 3.0.2., in which a greater magnitude of
curve represents higher frequency dosing. Via telecon-
ferences, a qualitative analytic approach was used to
interpret the dose density curves and the relationships
between dose density and VIPN severity.
Results
Demographics
A total of 1,539 assessments were performed on
128 children in their first year of treatment. Of those
children, 109 were able to provide multiple complete
scores over the first year, and 19 were never able to
provide a complete score (excluded from most anal-
yses). Table 2 presents sample demographic charac-
teristics based on the total number of assessments
performed in the first year. Using data from those pro-
viding complete TNS©-PV scores (N= 109), there were
nearly an equal number of assessments performed on
males (47%) and females (53%) and most were per-
formed on Caucasian (88%) and non-Hispanic (78%)
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subjects. The mean number of TNS©-PV assessments
conducted on each child was 12.3 (SD= 6.4). Themean
age was 7.5 years, with a range at baseline of 1–19
years. When comparing the analyzed sample of chil-
dren who provided full TNS©-PV scores (n= 109) to
those children excluded from the analysis (n=19),
the children in the excluded cohort were significantly
younger (p< 0.001) and more were males (p< 0.001).
VIPN incidence, patterns, and severity
Over the first year of treatment, 78% of the chil-
dren who provided complete TNS©-PV scores devel-
oped VIPN. Mean total and item scores, ranges, and
SDs are presented in Table 3. Mean TNS©-PV individ-
ual item scores were low for most children.
Mean sensory and motor CTCAE© scores are also
provided in Table 3. CTCAE©-derived grades 1, 2, 3,
and 4 sensory VIPN occurred in 31%, 3.2%, 1.6%, and
0%, and motor VIPN in 18%, 4.4%, 1.9%, and 0% of
children, respectively. Balis scale grades were similar
to the CTCAE grades. CTCAE© motor and sensory
scores were>0 in 69% and 74% of the sample,
respectively.
FACES© pain scores were attainable in nearly all
children (96%). Approximately 44% reported VIPN-
associated pain (FACES© score >0). Pain severity was
mild in most cases (mean score= 0.19; SD= 0.72).
PNPS©-5 item scores – attainable in fewer chil-
dren (83%) – suggest that foot pain, although mild,
was slightly more severe than other pain types
(mean/SD=0.11/0.52) (Table 3).
Figures 1A and 1B illustrate patterns of individual
TNS©-PV item scores over the first 12 months of treat-
ment. Reflexes were affected the most, followed by
vibration sensibility and strength. Most item scores
were highest at month 6. Cranial neuropathy was mini-
mal, worsened in month 2, and completely resolved by
month 11.
The cluster analysis revealed three distinct VIPN
severity subgroups (high, middle, and low) (Fig. 2).
TNS©-PV scores in the high cluster/cluster 1 sub-
group (n= 14) initially peaked 4months from treatment
onset, which was approximately 2months after reach-
ing the maximum vincristine dose density (time of
peak vincristine administration frequency), illustrating
a coasting effect. TNS©-PV scores for the middle clus-
ter/cluster 2 subgroup (n= 70) peaked at month 2 and
then remained essentially stable over the 12 month
assessment period. Some patients (n=25) fell into
the low VIPN severity cluster/cluster 3. These patients
experienced minimal VIPN and their TNS©-PV scores
spiked at months 2, 6, and 10. In all cluster subgroups,
VIPN scores remain abnormal at the 12-month time
point.
Figure 3 and Table 4 illustrate the variation in
individual TNS©-PV items scores by cluster grouping.
When compared to the other item scores and regard-
less of cluster grouping, tendon reflex scores were the
highest (most abnormal), followed by diminished vibra-
tion sensation, and then altered strength. Cranial neu-
ropathy occurred infrequently. Table 4 also shows that
all pain item scores were higher in cluster 1 than in the
other two clusters.
CTCAE© grade cluster patterns were very sim-
ilar to those of the TNS©-PV (Table 4). Regardless
of measurement approach, three separate clusters
emerged. Mean CTCAE© scores by cluster sug-
gest that sensory neuropathy was more severe than
motor (Table 4). Additional analyses were conducted
to assess for confounding variables that could have
influenced the cluster analysis findings. We found
differences in the cluster groupings based on the
enrollment site. TNS©-PV scores were significantly
higher in patients enrolled at the George Washington
University/Children’s National Medical Center than in
patients enrolled at the other sites (p=0.002). Fewer
George Washington University patients fell into the
low TNS©-PV and CTCAE© clusters when compared
to the other sites. Differences in VIPN scores by enroll-
ment site could not be explained based on differences
in age, gender, race, or pharmacokinetic parameters
(vincristine clearance or area under the curve).
We conducted analyses to explore whether
steroid-induced myopathy could have confounded the
VIPN scores. A case-by-case analysis of all patients
with high TNS©-PV motor scores was conducted to
identify muscle weakness in patients with no other
signs of VIPN. Because we found no cases of motor
score weakness in the first 6–8 weeks of vincristine
treatment (when steroid myopathy is most likely to
occur) in the absence of other VIPN signs and symp-
toms, motor scores probably do not reflect steroid
myopathy.
Predictors of more severe VIPN
TNS©-PV scores were positively associated with
age (r= 0.31; p< 0.0001) (Table 5). All individual
TNS©-PV item scores were higher in older children
except for the autonomic and cranial neuropathy
items. CTCAE© sensory and motor grades also were
higher in older children. No significant differences in
neuropathy scores based on race or gender were
found.
TNS©-PV total and individual item scores did not
significantly improve in months 8–12 despite decreas-
ing vincristine dose density over the same time (Fig. 2).
Some children (n=14) experienced severe VIPN that
appears to be unrelated to dose density (Fig. 2).
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Table 2. Sample demographics.
Total sample
Analyzed sample with
Full TNS©-PV Scores Excluded sample
Sample (N) 128 109 19
Assessments (N) 1,539 1,338 201
Age
Mean (SD) 6.84 (4.16) 7.45 (4.10) 2.78 (1.20)*
Range 1–19 1–19 1–10
Gender, n (%)
Male 777 (50.5) 631 (47.2) 146 (72.6)*
Female 763 (49.5) 707 (52.8) 55 (27.4)
Race
Caucasian 1,360 (88.3) 1,177 (88.0) 183 (91.0)
African American 77 (5.0) 77 (5.8) 0 (0.0)
Asian 4 (0.3) 4 (0.3) 0 (0.0)
Unknown 98 (6.4) 80 (6.0) 18 (9.0)
Ethnicity
Hispanic 186 (12.1) 144 (10.8) 42 (20.9)
Non-Hispanic 1,178 (76.5) 1,042 (77.9) 136 (67.7)
Unknown 175 (11.4) 152 (11.4) 23 (11.4)
Assessments per patient
Mean (SD) 12.02 (6.63) 12.27 (6.42) 10.58 (7.76)
Range 1-25 1-25 1-22
TNS©-PV, Total Neuropathy Score-Pediatric Vincristine.
*Significantly different from analyzed sample at p<0.0001 based on a two-tailed t-test.
Table 3. Mean VIPN and pain scores (n= 109).
Scale and items
Assessments
obtained Range Mean SD
TNS©-PV items N (Assessments) %
Paresthesias 1,259 94 0–4 0.19 0.75
Numbness 1,258 94 0–4 0.13 0.62
Neuropathic pain 1,264 94 0–4 0.23 0.80
Temperature 1,153 86 0–4 0.32 0.81
Vibration 1,118 84 0–4 0.73 1.12
Strength 1,224 91 0–4 0.54 0.79
Reflex 1,229 92 0–4 1.52 1.30
Autonomic 1,318 99 0–4 0.52 0.79
Cranial 1,318 99 0–2 0.06 0.27
Total score 1,066 80 0–22 4.08 3.56
CTCAE© sensory 1,133 85 0–3 0.34 0.62
CTCAE© motor 1,133 85 0–3 0.43 0.61
FACES© 1,286 96 0–5 0.19 0.72
NPS©-CIN items
Feet pain 1,110 83 0–5 0.10 0.52
Hand pain 1,111 83 0–4 0.04 0.30
Jaw pain 1,110 83 0–5 0.04 0.26
Numb pain 1,105 83 0–5 0.09 0.46
Tingly pain 1,103 82 0–5 0.09 0.47
CTCAE©, Common Terminology Criteria; TNS©-PV, Total Neuropathy Score-Pediatric Vincristine; VIPN, vincristine-induced peripheral
neuropathy.
Discussion
Our use of the sensitive TNS©-PV assessment tool
revealed that 78%of children developed VIPN and 44%
reported pain; however, symptom severity was gener-
ally low. Although the incidence rates we found are dis-
cordant with other published reports, we believe that
our findings are valid because we used rigorous and
validated methods for quantifying the VIPN phenotype.
The large sample size (1,338 assessments in 109 chil-
dren), longitudinal study design (12months), and use of
TNS©-PV allowed more accurate VIPN characterization
than that of previously published studies using smaller
samples and retrospective or cross-sectional designs.
These factors may explain the higher VIPN incidence
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Figure 1. (A) Total Neuropathy Score-Pediatric Vincristine (TNS©-PV) Subjective Symptom Scores in first 12 months (n=109).
(B) TNS©-PV Objective Sign Scores in first 12 months (n= 109).
rates discovered in this study. When comparing VIPN
rates identified using the TNS©-PV to the traditional
NCI CTCAE©, the TNS-PV identified slightly more chil-
dren with VIPN. Our findings are similar (but less strik-
ing) than results reported by Gilchrist et al., who dis-
covered that the CTCAE© failed to uncover VIPN in
40% of children 5–18 years of age with ped-mTNS©
scores≥5 (Gilchrist et al., 2014). It is highly likely that
future use of a TNS©-based assessment approach
will lead to higher and more accurate VIPN incidence
rates than have previously been reported based on the
CTCAE©.
VIPN did not improve despite children receiving
less vincristine in months 8–12. Additional research is
ongoing to assess long-term outcomes in this cohort
beyond the 12 month time point.
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Figure 2. Total Neuropathy Score-Pediatric Vincristine
(TNS©-PV) Mean Total Score and dose density by cluster
(n=109).
VIPN scores were worse in older children. Our
results may partly relate to the enhanced ability of older
children to describe their symptoms, whereas younger
children may lack the vocabulary or the understanding
to do so. Our findings are consistent with results
published by Liew et al. showing that VIPN severity
in adults with ALL was also worse in older patients
(p= 0.0006) (Liew et al., 2013). Our findings are also
Figure 3. Mean Total Neuropathy Score-Pediatric Vincristine
(TNS©-PV) Item Scores by cluster (n= 109).
consistent with the adult ALL literature and seem
to confirm anecdotal clinical observations that older
children experienceworse VIPN. In order to validate our
findings further, more accurate and precise methods
to assess VIPN in younger individuals who cannot
describe their symptoms are still needed.
While most children experienced only mild to mod-
erate VIPN, others developed severe symptoms. High
cumulative vincristine dosage, as well as more fre-
quent dosing, and prolonged treatment duration are
well-known predisposing factors for the development
of VIPN (Verstappen et al., 2005; Gomber et al., 2010).
Other factors influencing neuropathy may include
Table 4. VIPN and pain by cluster (n=109 children).
Cluster 1 (187
assessments
from 14 children)
Cluster 2 (762
assessments
from 70 children)
Cluster 3 (389
assessments
from 25 children)
n Mean SD n Mean SD n Mean SD
TNS©-PV items
Paresthesias 181 0.49 1.14 702 0.18 0.74 376 0.06 0.40
Numbness 182 0.53 1.16 700 0.09 0.54 376 0.02 0.18
Neuropathic pain 181 0.67 1.30 707 0.19 0.72 376 0.09 0.51
Temperature 177 0.92 1.31 622 0.30 0.76 354 0.05 0.27
Vibration 173 1.51 1.46 590 0.77 1.11 355 0.28 0.69
Strength 175 1.25 1.15 681 0.52 0.71 368 0.22 0.46
Reflex 174 2.53 1.47 696 1.57 1.24 359 0.91 0.99
Autonomic 185 0.84 0.91 749 0.51 0.79 384 0.37 0.69
Cranial 184 0.11 0.33 750 0.06 0.27 384 0.04 0.22
Total score 165 8.02 5.22 559 4.22 3.01 342 1.94 1.86
CTCAE© motor 161 0.90 0.95 629 0.33 0.58 343 0.11 0.32
CTCAE© sensory 161 1.03 0.89 629 0.42 0.55 343 0.18 0.37
FACES© 180 0.68 1.34 729 0.13 0.56 377 0.06 0.41
NPS©-CIN items
Feet pain 168 0.42 1.09 601 0.06 0.34 341 0.03 0.29
Hand pain 168 0.17 0.67 602 0.02 0.20 341 0.01 0.10
Jaw pain 168 0.10 0.42 601 0.03 0.20 341 0.02 0.27
Numb pain 168 0.42 1.03 597 0.04 0.22 340 0.02 0.26
Tingly pain 168 0.29 0.90 596 0.06 0.36 339 0.04 0.32
CTCAE©, Common Terminology Criteria; TNS©-PV, Total Neuropathy Score-Pediatric Vincristine; VIPN, vincristine-induced peripheral
neuropathy.
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Table 5. VIPN and pain by age.
<5years*(630
assessments
from 53 children)
5–9 years*(563
assessments
from 51 children)
≥10years*(346
assessments
from 37 children)
n Mean SD n Mean SD n Mean SD
TNS©-PV items
Paresthesias 434 0.10 0.46 557 0.15 0.65 339 0.35 1.05
Numbness 433 0.04 0.26 556 0.05 0.37 340 0.38 1.03
Neuropathic pain 440 0.21 0.66 558 0.16 0.68 339 0.34 1.01
Temperature 307 0.15 0.44 527 0.30 0.83 336 0.49 0.98
Vibration 266 0.44 0.66 523 0.59 1.05 335 1.18 1.37
Strength 459 0.43 0.65 538 0.48 0.68 333 0.73 0.99
Reflex 496 1.31 1.21 526 1.33 1.18 333 1.99 1.39
Autonomic 623 0.58 0.82 555 0.50 0.78 341 0.49 0.78
Cranial 624 0.10 0.37 555 0.07 0.29 340 0.07 0.27
Total score 228 3.29 2.35 507 3.48 3.07 331 5.53 4.25
CTCAE© motor 543 0.24 0.52 485 0.27 0.54 281 0.56 0.77
CTCAE© sensory 543 0.31 0.53 485 0.34 0.52 281 0.67 0.74
FACES© 586 0.15 0.65 548 0.13 0.58 335 0.29 0.90
NPS©-CIN items
Feet pain 276 0.10 0.37 532 0.05 0.34 333 0.20 0.79
Hand pain 275 0.03 0.19 532 0.02 0.20 333 0.09 0.46
Jaw pain 274 0.02 0.12 532 0.05 0.33 333 0.04 0.26
Numb pain 268 0.07 0.35 531 0.02 0.18 333 0.20 0.73
Tingly pain 267 0.08 0.35 530 0.06 0.38 333 0.14 0.63
CTCAE©, Common Terminology Criteria; TNS©-PV, Total Neuropathy Score-Pediatric Vincristine; VIPN, vincristine-induced peripheral
neuropathy.
*Age-based samples are not mutually exclusive because multiple assessments from the same child were obtained over the first year, as the
child aged.
hepatic insufficiency, nutritional deficits (Kumar, 2007),
and genetics (Argyriou et al., 2012). For example, the
CYP3A family of enzymes that metabolizes vinca
alkaloids such as vincristine is highly polymorphic,
which may result in differential gene expression (Egbe-
lakin et al., 2011). Preliminary evidence suggests that
patients who are CYP3A5 high expressers experience
less VIPN than those who are CYP3A5 low expressers
(Dennison et al., 2006; Egbelakin et al., 2011). Because
CYP3A5 is more commonly highly expressed in African
Americans compared to Caucasians, Caucasian chil-
dren as a population may be at higher risk of devel-
oping VIPN. We did not observe this association, pos-
sibly due to the small number of African American
patients in our study population. In a recent study by
Diouf et al., another genetic polymorphism was asso-
ciated with both greater risk of and more severe VIPN
(Diouf et al., 2015). Our understanding of the factors
that predispose these higher risk children to VIPN is
incomplete.
Our results may inform future predictive algo-
rithms to facilitate identification of patients in both
the high and low VIPN clusters. For the high VIPN
group, this could provide an opportunity to avoid sig-
nificant, irreversible toxicity in children with low risk
ALL by pre-emptively decreasing vincristine dosing,
completely eliminating vincristine from ALL therapy,
or focusing study of neuroprotective agents in this
high-risk population. At the other end of the spectrum,
children who are in the low VIPN group but who are
identified as having high-risk ALL might benefit from
dose intensification with vincristine.
Our findings can be used to inform families about
common VIPN signs and symptoms, when they are
most likely to occur, and how severe they may be.
Families should know that VIPN will likely be an issue
throughout the first year of ALL treatment and possibly
longer. Because ALL is most prevalent in children 2–3
years of age (American Cancer Society, 2013) who
may not be able to report VIPN symptoms, increased
knowledge of VIPN will enable everyone – clinicians
and families – to anticipate problems in very young
children so that symptoms can be reported as early as
possible.
Our study provides new information about VIPN
patterns, severity, clinical manifestations, and predic-
tors, which are fundamental to identifying approaches
to treatment or prevention of VIPN. If severity is asso-
ciated with specific germline mutations, prospective
genetic testing might be used to identify high-risk
patients. If drug exposure or other pharmacokinetic
parameters is associated with symptom severity, fast
metabolizers might tolerate and benefit from higher
than current standard vincristine dosing to optimize
survival. Development of such a personalized approach
will require a valid and reliable approach to quantifying
the VIPN phenotype in future studies correlating
biomarkers to outcomes.
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Our study has several limitations. First, children
who could not cooperate with a full TNS©-PV assess-
ment (n= 19) were excluded from our main analysis.
Those excluded were younger and more likely to be
male. Because older patients develop more severe
neuropathy, excluding young patients from the analy-
sis may have resulted in an inflated incidence estimate.
We were able to capture deep tendon reflex scores in
79% of the excluded subset. Reflex scores worsened
over time in 50% of a small subset of the excluded
patients (four of eight) who provided more than one
score over the first year. These limited findings support
our main finding that VIPN is less severe in younger
children. In young children, reflex assessment appears
to be the most feasible and valid way to assess VIPN,
including changes over time.
The cluster analysis results may have been con-
founded by unknown differences inherent to the enroll-
ment site. Although we assessed for the presence of
confounders that might explain this finding, the study
was underpowered to detect differences in demo-
graphic or other variables by enrollment site. One pos-
sible explanation for the higher VIPN scores reported
by participants at the George Washington University
is that, at this site, a neurologist conducted 20% of
the TNS© assessments. However, CTCAE© grades
obtained by non-neurologist clinicians at this site, who
were blinded to the TNS©-PV scores, were highly cor-
related with the TNS© scores (r= 0.81; p< 0.00001).
It is unlikely that the higher scores obtained at the
GeorgeWashington University were in any way related
to evaluator skill.
Another limitation is that we retained the constipa-
tion item within the TNS©-PV, even though our previ-
ous psychometric work suggests that the constipation
item may be an invalid measure of autonomic neu-
ropathy; many factors influence constipation incidence
such as opioid use, diet, hydration, and activity patterns
(Smith et al., 2013). However, we retained this item
within the TNS©-PV because constipation severity
cluster analysis patterns (Fig. 3) mirrored other items,
providing some evidence of its validity. Autonomic
neuropathy manifesting as constipation, dizziness, or
changes in skin temperature is difficult to quantify.
Gilchrist and Tanner used the ped-mTNS© to quan-
tify autonomic neuropathy by asking patients about
dizziness and hot or cold sensations in the extremities
and were unable to support the item’s validity when
comparing scores to those obtained in normal controls
(Gilchrist and Tanner, 2013). Autonomic neuropathy
may be too difficult to capture and possibly should
be eliminated from future pediatric TNS© versions.
Another limitation is that use of analgesic medications
such as gabapentin, pregabalin, or narcotics was not
quantified and may have impacted pain assessments
in patients with VIPN. Last, dose density and cluster
analysis interpretation were qualitative in nature.
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